Stockscreener 앱 받기
1.40
5.26%
0.07
시간 외 거래:
1.40
전일 마감가:
$1.33
열려 있는:
$1.3
하루 거래량:
4.46M
Relative Volume:
0.64
시가총액:
$422.80M
수익:
$160.01M
순이익/손실:
$-546.38M
주가수익비율:
-0.7629
EPS:
-1.835
순현금흐름:
$-118.92M
1주 성능:
+10.24%
1개월 성능:
-16.67%
6개월 성능:
+10.24%
1년 성능:
+12.00%
1일 변동 폭
$1.28
$1.43
1주일 범위
$1.28
$1.43
52주 변동 폭
$0.8511
$2.73
퍼시픽 바이오 사이언스 Stock (PACB) Company Profile
명칭
Pacific Biosciences Of California Inc
전화
650-521-8000
주소
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.40 | 401.66M | 160.01M | -546.38M | -118.92M | -1.835 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
퍼시픽 바이오 사이언스 Stock (PACB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-06 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-11-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-04-18 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-14 | 개시 | Stephens | Overweight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-17 | 업그레이드 | UBS | Neutral → Buy |
| 2023-10-31 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-06-30 | 개시 | Goldman | Buy |
| 2023-05-10 | 개시 | Barclays | Equal Weight |
| 2023-03-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2023-01-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-01-21 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Neutral |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-09-27 | 개시 | Canaccord Genuity | Buy |
| 2021-02-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-03-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | 개시 | Cowen | Outperform |
| 2017-11-03 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | 다운그레이드 | CL King | Buy → Neutral |
| 2016-11-03 | 재확인 | Cantor Fitzgerald | Buy |
| 2016-06-27 | 개시 | CL King | Buy |
| 2016-04-15 | 개시 | First Analysis Sec | Overweight |
| 2016-02-04 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-10-23 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | 개시 | Cantor Fitzgerald | Buy |
| 2015-02-04 | 재확인 | Maxim Group | Buy |
| 2013-09-26 | 재확인 | Maxim Group | Buy |
| 2013-01-14 | 재확인 | Maxim Group | Buy |
모두보기
퍼시픽 바이오 사이언스 주식(PACB)의 최신 뉴스
DNA Sequencing Market size to hit $108.95 Billion by 2035 | Top - openPR.com
Canaccord reiterates Pacific Biosciences stock rating on new chemistry - Investing.com
PacBio (PACB) Collaborates on Groundbreaking Trillion Gene Atlas Project - GuruFocus
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo! Finance Canada
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative - marketscreener.com
Inside the trillion-gene atlas training AI to design new medicines - Stock Titan
Pacific Biosciences of California unveils DNA sequencing method boosting accuracy to 99.9 percent - Traders Union
Volume Summary: Does Pacific Biosciences of California Inc have a sustainable dividend2026 Geopolitical Influence & AI Forecasted Stock Moves - baoquankhu1.vn
Pullback Watch: Can Pacific Biosciences of California Inc reach all time highs this yearWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Pacific Biosciences of California urges last call for webinar on HiFi sequencing advances in cancer research - Traders Union
PacBio and DNAstack collaborate on global HiFi genome network hub - MSN
Pacific Biosciences of California introduces HiFi sequencing for comprehensive cancer analysis - Traders Union
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio - geneonline.com
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
Pacific Biosciences of California technology maps cancer structural variants in single platform advance - Traders Union
PACB,TAL Options - Finviz
PACB,TAL Volatility & Greeks - Finviz
Chart Watch: Will Pacific Biosciences of California Inc outperform during market ralliesWeekly Earnings Recap & Low Risk Entry Point Guides - baoquankhu1.vn
Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance
HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union
Pacific Biosciences of California reports prelim Q4, FY revenue above estimate - MSN
Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks
Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com
Patent deal locks in protections for Pacific Biosciences (NASDAQ: PACB) with PGI - Stock Titan
Pacific Biosciences of California, Inc. Announces Chief Accounting Officer Changes, Effective March 21, 2026 - marketscreener.com
PACB - Finviz
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz
PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat
Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada
Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK
PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm
Pacific Biosciences of California unveils HiFi sequencing for comprehensive multiomic analysis - Traders Union
PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com
PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks
Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com
PacBio Appoints New Board Member - Intellectia AI
AI biotech leader Chris Gibson joins PacBio (PACB) board of directors - Stock Titan
AI drug discovery founder from Recursion joins PacBio board - Stock Titan
Pacific Biosciences of California, Inc. $PACB Shares Sold by ARK Investment Management LLC - MarketBeat
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 By Investing.com - Investing.com Canada
Farmer Michele sells Pacific Biosciences (PACB) shares for $4510 - Investing.com
Pacific Biosciences of California (NASDAQ:PACB) Insider Christian Henry Sells 12,497 Shares - MarketBeat
PRISM 2026 set to shape genomics future, Pacific Biosciences of California asserts - Traders Union
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - Finviz
Intuitive Surgical Expands Direct Operational Presence in Europe - Finviz
Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB) - Yahoo Finance
Equity awards to Pacific Biosciences (PACB) officer disclosed - Stock Titan
PACB (PACB) grants James R. Gibson II 667,696 options and 333,848 RSUs - Stock Titan
Pacific Biosciences (PACB) officer receives large option and RSU awards - Stock Titan
Large equity grants to PacBio (PACB) executive highlight retention focus - Stock Titan
퍼시픽 바이오 사이언스 (PACB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
퍼시픽 바이오 사이언스 주식 (PACB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
6,504 |
9,847 |
2,243,634 |
| Farmer Michele | See Remarks |
Mar 03 '26 |
Sale |
1.51 |
2,979 |
4,510 |
305,948 |
0.85%
1.86%
자본화:
|
볼륨(24시간):